There are 2 versions of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (3)

Short Titles

Short Titles - Senate

Short Title(s) as Reported to Senate

Affordable Prescriptions for Patients Act of 2019

Short Title(s) as Introduced

Affordable Prescriptions for Patients Act of 2019

Official Titles

Official Titles - Senate

Official Titles as Introduced

A bill to amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.


Actions Overview (2)

Date Actions Overview
06/28/2019Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.
05/09/2019Introduced in Senate

All Actions (4)

Date All Actions
06/28/2019Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.
Action By: Senate
06/28/2019Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.
06/27/2019Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
05/09/2019Read twice and referred to the Committee on the Judiciary.
Action By: Senate

Cosponsors (13)


Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Related Documents
Senate Judiciary05/09/2019 Referred to
06/27/2019 Markup by
06/28/2019 Reported by

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Latest Summary (2)

There are 2 summaries for S.1416. View summaries

Shown Here:
Reported to Senate (06/28/2019)

Affordable Prescriptions for Patients Act of 2019

This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a hard switch or a soft switch. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration’s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A follow-on product is a changed, modified, or reformulated version of a manufacturer’s already-approved drug or biological product that still treats the same medical condition.

A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product.

A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition.

This bill also limits the number of patents that may be included in infringement claims brought by approved biological product license holders against applicants for a biosimilar product license.